Search Results

Updated 1-Year BIOSOLVE-IV Data Presented for Biotronik's Magmaris Resorbable Scaffold

June 7, 2019–Biotronik announced that updated 12-month follow-up cohort results from the first 800 patients in the BIOSOLVE-IV registry were presented by the study's Principal Investigator Stefan Verheye, MD, at EuroPCR held May 21–24 in Paris, France.

EuroPCR Session Examines Evidence for Bioresorbable Scaffolds

May 22, 2014—At the EuroPCR 2014 congress in Paris, France, a session was devoted to the development of evidence for bioresorbable vascular scaffolds, which represent a new era of vascular restoration in interventional cardiology.  As summarized in the EuroPCR announcement, a panel of experts analyzed the available data and concluded that bioresorbable, fixed-strut vascular scaffolds are associated with increased acute thrombogenicity due to flow disturbances.

Biotronik Announces Additional Investment in Magmaris Resorbable Magnesium Scaffold

May 23, 2018—Biotronik announced that it will further invest in the company’s Magmaris resorbable magnesium scaffold (RMS) as additional data continue to support the scaffold’s safety and efficacy.

Biotronik’s Dreams 3G Scaffold Shows Vascular Healing Process at 1 Year in OCT Analysis From BIOMAG-I FIH Study

September 1, 2023—Biotronik announced that new data from the BIOMAG-I first-in-human trial demonstrated the vascular healing process after the implantation of the company’s third-generation resorbable magnesium scaffold (RMS), Dreams 3G.

Biotronik's Magmaris Resorbable Scaffold Shows Reduced Risk of Thrombosis

May 17, 2017—Biotronik announced data demonstrating that the company's Magmaris resorbable scaffold offers a reduced risk of thrombus formation compared with a polymeric scaffold (Absorb, Abbott Vascular) were presented at the EuroPCR 2017 conference in Paris, France.

HighLife TMVR System Receives CE Mark Approval

January 26, 2026–HighLife SAS, a France-based developer of transcatheter solutions for structural heart disease, announced that it has received CE Mark approval for the HighLife transcatheter mitral valve replacement (TMVR) system.

AHA and ACC Publish 2018 Cholesterol Guidelines

November 10, 2018—The American Heart Association (AHA) and American College of Cardiology (ACC) announced the publication of 2018 cholesterol guidelines recommending more personalized risk assessments and new cholesterol-lowering drug options for those at highest risk for cardiovascular disease.

Device Closure for Ventricular Septal Defect After Myocardial Infarction

Acquired ventricular septal defect (VSD) is one of the three major mechanical complications of acute myocardial infarction (AMI), the other two being acute mitral regurgitation and rupture of the ventricular free wall.